Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770515 | 0.90 | EPHX2 (0.56) | EPHX2HSD11B1MEN1KMT2AHTT | |
| SCHEMBL771489 | 0.88 | EPHX2 (0.56) | EPHX2HSD11B1ALDH1A1EPHX1 | |
| SCHEMBL770745 | 0.87 | HSD11B1 (0.49) | EPHX2HSD11B1ALDH1A1MEN1KMT2A | |
| SCHEMBL771352 | 0.83 | HSD11B1 (0.52) | EPHX2HSD11B1ALDH1A1SMN1; SMN2EPHX1 | |
| SCHEMBL770825 | 0.80 | KMT2A (0.49) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL772616 | 0.80 | EPHX2 (0.58) | EPHX2ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL770251 | 0.78 | KDM4E (0.41) | HSD11B1ALDH1A1SMN1; SMN2HTTEPHX1 | |
| SCHEMBL770005 | 0.78 | HDAC4 (0.37) | HSD11B1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL770368 | 0.78 | EPHX2 (0.58) | EPHX2MEN1KMT2AHTTEPHX1 | |
| SCHEMBL770823 | 0.75 | EPHX2 (0.53) | EPHX2HSD11B1MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | EPHX2 1149/4885HSD11B1 1/4885ALDH1A1 144/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | EPHX2 1153/4885HSD11B1 1/4885ALDH1A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.